Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age.

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Biohaven Pharmaceuticals, Inc.
Updated on 25 October 2022


The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).

Condition Acute Treatment of Migraine
Treatment Rimegepant / BHV3000
Clinical Study IdentifierNCT04743141
SponsorBiohaven Pharmaceuticals, Inc.
Last Modified on25 October 2022


Yes No Not Sure

Inclusion Criteria

History of migraine (with or without aura) for ≥ 6 months before Screening
History of 1 to 8 moderate or severe attacks per month during the 2 months prior to enrollment
1 or more migraine days requiring treatment during the Observation Phase
Prophylactic migraine medication is permitted if the dose has been stable for at least 12 weeks prior to the Baseline Visit
Ability to distinguish between migraine and other types of headaches
Weight ≥ 40 kg at the Screening Visit
Adequate venous access for blood sampling
Male and female participants ≥ 6 to < 18 years of age (participants must not reach their 18th birthday before enrollment into the study)

Exclusion Criteria

History of cluster headache or hemiplegic migraine headache
Confounding and clinically significant pain syndrome
Current uncontrolled and/or untreated psychiatric condition for a minimum of 6 months prior to the Screening Visit (lifetime history of psychosis and/or mania are excluded)
History of suicidal behavior or major psychiatric disorder
Current diagnosis or history of substance abuse; positive drug test at Screening
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note